Follow
Nabanita Mukherjee
Nabanita Mukherjee
Associate Director, AbbVie
Verified email at abbvie.com
Title
Cited by
Cited by
Year
Toward defining the autoimmune microbiome for type 1 diabetes
A Giongo, KA Gano, DB Crabb, N Mukherjee, LL Novelo, G Casella, ...
The ISME journal 5 (1), 82-91, 2011
9312011
Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes
CT Brown, AG Davis-Richardson, A Giongo, KA Gano, DB Crabb, ...
PloS one 6 (10), e25792, 2011
8612011
PANGEA: pipeline for analysis of next generation amplicons
A Giongo, DB Crabb, AG Davis-Richardson, D Chauliac, JM Mobberley, ...
The ISME journal 4 (7), 852-861, 2010
1362010
Mortality and cardiovascular disease among older live kidney donors
PP Reese, RD Bloom, HI Feldman, P Rosenbaum, W Wang, P Saynisch, ...
American Journal of Transplantation 14 (8), 1853-1861, 2014
972014
Template matching for auditing hospital cost and quality
JH Silber, PR Rosenbaum, RN Ross, JM Ludwig, W Wang, BA Niknam, ...
Health services research 49 (5), 1446-1474, 2014
782014
Improving Medicare's hospital compare mortality model
JH Silber, VA Satopää, N Mukherjee, V Rockova, W Wang, AS Hill, ...
Health services research 51, 1229-1247, 2016
312016
Bayesian Learning of Dynamic Multilayer Networks
D Durante, N Mukherjee, RC Steorts
JMLR 18 (43), 1−29, 2017
222017
An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma
A Younes, G Salles, RG Bociek, G Martinelli, D Caballero, EG Barca, ...
Blood 124 (21), 1718, 2014
162014
Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).
R Salazar, C Verslype, E Baudin, SK Libutti, JC Yao, R Buzzoni, ...
Journal of Clinical Oncology 33 (15_suppl), 4102-4102, 2015
152015
Convergence analysis of some multivariate Markov chains using stochastic monotonicity
K Khare, N Mukherjee
112013
An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular …
A Younes, G Salles, G Martinelli, RG Bociek, DC Barrigon, EG Barca, ...
Blood 126 (23), 1493, 2015
92015
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
R Popovic, F Dunbar, C Lu, K Robinson, D Quarless, SE Warder, ...
American Journal of Hematology 97 (2), E47, 2022
72022
S146: venetoclax in patients with chronic lymphocytic leukemia with 17P deletion: 6-year follow-up and genomic analyses in a pivotal phase 2 trial
S Stilgenbauer, E Tausch, AW Roberts, MS Davids, B Eichhorst, M Hallek, ...
HemaSphere 6, 47-48, 2022
42022
Bayesian learning of dynamic multilayer networks
D Durante, N Mukherjee, RC Steorts
arXiv preprint arXiv:1608.02209, 2016
42016
CBEZ235Z2401: Randomized phase II study of BEZ235 or everolimus (EVE) in patients with advanced pancreatic neuroendocrine tumors (pNET)
S Libutti, R Garcia-Carbonero, EM Wolin, A Custodio, JC Yao, ...
Neuroendocrinology 102 (1-2), 131-131, 2015
32015
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del (17p) chronic lymphocytic leukemia
S Stilgenbauer, E Tausch, AW Roberts, MS Davids, B Eichhorst, M Hallek, ...
Blood Advances, 2024
2024
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
M Herling, C Dearden, F Zaja, D El-Sharkawi, W Ding, M Bellido, A Khot, ...
Blood Advances, 2024
2024
MO50-5 Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
K Izutsu, H Goto, M Kizaki, M Yamaguchi, N Fukuhara, K Kato, T Saito, ...
Annals of Oncology 34, S1428, 2023
2023
Algorithms for improving efficiency of discrete Markov chains
N Mukherjee, G Casella, K Khare
Indian Journal of Pure and Applied Mathematics 48 (4), 495-511, 2017
2017
The Autoimmune Metagenome for Type 1 Diabetes Reveals Differences in the Metabolic Potential of an Aberrant Gut Micro biota
CT Brown, A Giongo, AG Davis-Richardson, KA Gano, DB Crabb, ...
DIABETES 60, A3-A3, 2011
2011
The system can't perform the operation now. Try again later.
Articles 1–20